| Assay ID | Title | Year | Journal | Article |
|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID298509 | Inhibition of CYP2D6 | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID298520 | Cmax in Wistar rat plasma at 1 mg/kg, iv | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID298516 | AUC in Wistar rat plasma at 3 mg/kg, po | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID298503 | Antagonist activity at human recombinant GHSR1a expressed in HEK293F cells by [35S]GTP-gamma-S binding assay | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID298527 | Decrease in body weight in DIO C57BL/6 mouse at 30 mg/kg, po after 9 days | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID298535 | Binding affinity to calcium channel L type | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID648799 | Inhibition of muscarinic M2 receptor at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6
| Substituted azaquinazolinones as modulators of GHSr-1a for the treatment of type II diabetes and obesity. |
| AID298528 | Cmax in po dosed DIO C57BL/6 mouse after 5 hrs | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID298529 | Drug level in po dosed DIO C57BL/6 mouse brain after 5 hrs relative to plasma concentration | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID298517 | Cmax in Wistar rat plasma at 3 mg/kg, po | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID298521 | Half life in Wistar rat plasma at 1 mg/kg, iv | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID298505 | Cmax in Wistar rat at 3 mg/kg, po | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID648798 | Inhibition of muscarinic M1 receptor at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6
| Substituted azaquinazolinones as modulators of GHSr-1a for the treatment of type II diabetes and obesity. |
| AID298502 | Agonist activity at human recombinant GHSR1a expressed in HEK293F cells assessed as stimulation of [35S]GTP-gamma-S binding relative to ghrelin | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID298522 | Volume of distribution in Wistar rat plasma at 1 mg/kg, iv | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID298530 | Increase in food intake in DIO C57BL/6 mouse at 30 mg/kg, after 5 hrs relative to control | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID648797 | Inhibition of 5-HT2B at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6
| Substituted azaquinazolinones as modulators of GHSr-1a for the treatment of type II diabetes and obesity. |
| AID648796 | Inhibition of human Erg by patch clamp assay | 2012 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6
| Substituted azaquinazolinones as modulators of GHSr-1a for the treatment of type II diabetes and obesity. |
| AID298531 | Decrease in blood glucose level in DIO Wistar rat using at 10 mg/kg after 5 hrs by IPGTT test relative to control | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID298524 | Decrease in food intake in DIO C57BL/6 mouse at 30 mg/kg, po after 24 hrs relative to control | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID298501 | Displacement of [125I]ghrelin from ovine recombinant GHSR1a expressed in HEK293F cells after 6 hrs by scintillation proximity assay | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID298508 | Aqueous solubility at pH 7.2 | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID298534 | Binding affinity to motilin receptor | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID298506 | Clearance in Wistar rat at 1 mg/kg iv | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID298507 | Displacement of [125I]DIO from 5HT2c receptor | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID648794 | Displacement of [125I]-Ghrelin from human GHSR membranes overexpressing GSH-R1a by scintillation counting | 2012 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6
| Substituted azaquinazolinones as modulators of GHSr-1a for the treatment of type II diabetes and obesity. |
| AID298519 | AUC (0-t) in Wistar rat plasma at 1 mg/kg, iv | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID298533 | Binding affinity to 5HT2b receptor | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID298518 | Bioavailability in Wistar rat plasma at 3 mg/kg, po | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID648795 | Antagonist activity at mouse GSH-R1a receptor expressed in HEK293 cells assessed as inhibition of ghrelin-induced calcium mobilization after 5 mins by FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6
| Substituted azaquinazolinones as modulators of GHSr-1a for the treatment of type II diabetes and obesity. |
| AID298532 | Binding affinity to 5HT2a receptor | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
| Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. |
| AID1346009 | Human ghrelin receptor (Ghrelin receptor) | 2007 | Endocrinology, Nov, Volume: 148, Issue:11
| Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |